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Background: Aspirin is one of the most widely used non-steroidal anti-inflammatory drugs (NSAIDs). It is also a
commonly used anti-platelet drug, which inhibits the formation of the platelet activator, thromboxane A2 (TxA2) via
inhibition of cyclooxygenase-1 (COX-1). However, the presence of a patient subset that fails to respond to aspirin
despite reduced TxA2 concentrations suggests that the effect of aspirin might be more complex than exclusive
COX-1 inhibition.
Methods: In this study we evaluated the impact of in vivo oral administration of a standard anti-platelet dose (75 mg)
of aspirin in healthy volunteers on the acute impact of in vitro collagen-mediated platelet aggregation and generation
of platelet-derived TxA2 and the 12-lipoxygenase (LOX) metabolite 12-hydroxyeicosatetraenoic acid (12-HETE). The
eicosanoids were quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Results: Low-dose aspirin administration not only inhibited TxA2 generation but also decreased the production of
12-HETE. Furthermore, a significant correlation was observed between the levels of 12-HETE and collagen-induced
platelet aggregation. Pre-treatment of platelets with the 12-LOX inhibitor, baicalein, prior to activation attenuated
platelet aggregation.
Conclusions: These findings support a role for 12-HETE as a pro-aggregatory eicosanoid in platelet function and
suggest a role for 12-HETE in variable sensitivity to aspirin. The study also highlights a potentially important mechanism
by which aspirin impacts upon eicosanoid generation.
Keywords: Aspirin, Platelet, 12-HETE, Thromboxane, Eicosanoids, Anti-inflammatoryBackground
Aspirin (acetylsalicylic acid) is one of the most widely
used non-steroidal anti-inflammatory drugs (NSAIDs). In
addition to possessing anti-inflammatory properties at high
doses (1 g/day) [1] aspirin also demonstrates effective cardi-
oprotective properties at lower doses (75–150 mg/day) [2].
The proposed mechanism by which aspirin acts is by irre-
versible inhibition of cyclooxygenase 1 (COX-1) [3]. Enzyme
acetylation effectively blocks formation of the prostaglandin
intermediates, PGG2 and PGH2 and their resultant down-
stream bioactive products [4]. The cardioprotective anti-* Correspondence: phil.whitfield@uhi.ac.uk
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unless otherwise stated.platelet property of low-dose aspirin is attributed to irrevers-
ible inhibition of synthesis of a pro-thrombotic COX-1-
derived eicosanoid, thromboxane A2 (TxA2) [5], which is
derived from the polyunsaturated fatty acid substrate, ara-
chidonic acid (AA).
Platelet specificity of aspirin action is believed to stem
from the fact that platelets lack nuclear DNA, rendering
them incapable of de novo biosynthesis of COX-1, ensur-
ing that inhibition of COX-1 prevails for the lifespan of
the platelet. There is an increasing awareness of clinical
variability in anti-thrombotic response to aspirin, with a
significant proportion of patients failing to respond, a
phenomenon referred to as ‘aspirin resistance’ [6]. Esti-
mates of aspirin resistance vary widely (5-45%) [7], but re-
sistant patients are known to display an increased risk ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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association between aspirin-mediated inhibition of platelet
function and inhibition of TxA2 synthesis. This apparent
anomaly has been attributed to a perceived lack of reliabil-
ity of platelet function assays, on the assumption that re-
duced inhibition of TxA2 is the main contributory factor
in aspirin resistance [9].
Whilst TxA2 is undoubtedly an important mediator in
the platelet activation process, to date little attention has
been paid to other eicosanoids generated by platelets.
12-hydroxyeicosatetraenoic acid (12-HETE), formed by
the enzyme 12-lipoxygenase (12-LOX), is another major
platelet-derived eicosanoid, although its role in platelet
function remains unclear. Reports have suggested 12-
HETE to have both anti- and pro-thrombotic properties
[10-12]. It has also been suggested to play a role in pro-
moting expression of platelet CD62 (P-selectin) [13] and
is elevated in patients with essential hypertension [14].
The increasing recognition of the potential importance
of 12-HETE in platelet function has led to a recent re-
surgence of research in the area, which has resulted in
the development of novel 12-LOX inhibitors to help elu-
cidate the function of platelet 12-HETE and its potential
as a novel anti-platelet target [15,16]. The impact of as-
pirin on 12-HETE is not yet fully understood. In this
study we have investigated the association of TxA2 (mea-
sured as its degradation product TxB2) and 12-HETE
levels, with low-dose aspirin-mediated inhibition of
platelet aggregation in healthy volunteers.
Methods
Subjects
Healthy volunteers (n = 19) were recruited through the
Highland Clinical Research Facility. Subjects were free from
all non-steroidal anti-inflammatory drugs (NSAIDs) two
weeks prior to blood collection. A 5 ml blood sample was
drawn into trisodium citrate tubes (Monovette®, Sarstedt,
Leicester, UK) from the antecubital fossa (21G) before and
1.5 h after oral dosing with aspirin (Actavis, Barnstaple,
UK; 75 mg). For inhibitor studies, a further three healthy
volunteers were recruited and blood drawn as above. The
study was approved by the North of Scotland Research Eth-
ics Committee and the University of the Highlands and
Islands Ethics Committee, and was in accordance with the
Declaration of Helsinki and its amendments, with all volun-
teers providing written informed consent.
Measurement of platelet aggregation and inhibitor
studies
Platelet aggregation was measured in response to collagen
in platelet-rich plasma (PRP) derived from the freshly
drawn blood samples immediately before and 1.5 h after
aspirin administration. Briefly, fresh blood was centrifuged
(120 g for 10 min at room temperature), PRP aspiratedand the platelet count obtained on an AcT Diff 8 Blood
Counter (Beckman Coulter, High Wycombe, UK). The
remaining blood sample was centrifuged (1000 g for
10 min at room temperature) and the platelet poor plasma
(PPP) aspirated for use as a reference and to dilute the
PRP to a standard platelet count (150 × 106/ml). Standard-
ized PRP samples were aliquoted (500 μl) into glass
cuvettes with a micro-stirrer and pre-warmed to 37°C
prior to addition of type I collagen (Labmedics, Manchester,
UK; 2.5 μg/ml). Aggregation was recorded for 6 min using
a Chrono-Log 700 platelet aggregometer (Chrono-Log,
Haverford, PA, USA), at which point the activated platelets
were immediately stored at −80°C for subsequent eicosanoid
analysis. Aggregation was quantified as the area under the
curve (AUC) over the 6 min period post-activation. To
determine the effect of 12-LOX inhibition on platelet aggre-
gation, platelets were pre-incubated for 10 min with either
100 μM baicalein (Tocris Bioscience, Bristol, UK) or DMSO
as a vehicle control at a final concentration of 0.5% (v/v)
prior to addition of 1.25 μg/ml collagen; aggregation was
measured as described above and samples retained at the
end of the aggregation assay for subsequent eicosanoid
measurements.
LC-MS/MS analysis of platelet eicosanoids
Eicosanoids were isolated from the PRP following collagen
activation using solid-phase extraction (SPE) chromatog-
raphy (C18 500 mg, 6 ml, Waters, Manchester, UK). 1 ml
ice-cold methanol containing 1 ng of the deuterated
internal standards, PGE2-d4 and15-HETE-d8 (Cayman
Chemical, Ann Arbor, MI, USA), was added to 0.5 ml PRP
to precipitate proteins, and following centrifugation (600 g
for 10 min at 4°C), the supernatant was removed, diluted
to <10% methanol content by the addition of 9 ml ddH2O
and acidified to pH 3.5 with 1 M HCl. Acidified samples
were immediately added to SPE cartridges, which had
been conditioned with 2 × 6 ml methanol, followed by 2 ×
6 ml ddH2O. Samples were then washed with a further
6 ml ddH2O and 2 × 5 ml hexane before elution of the ei-
cosanoids with 2 × 3 ml ethyl acetate. The ethyl acetate
fraction was dried under vacuum and then resuspended in
100 μl 50:50 (v/v) solvent A:solvent B where solvent A
consisted of H2O:methanol 90:10 (v/v) containing 0.1%
(v/v) acetic acid and solvent B consisted of methanol con-
taining 0.1% (v/v) acetic acid. All solvents were LC-MS
grade (Fisher Scientific, Loughborough, UK).
Eicosanoids were separated on a Kinetex 1.7 μm XB-
C18 column (100 × 2.1 mm) (Phenomenex, Macclesfield,
UK) column using a Thermo Accela 1250 UHPLC system
(Thermo Scientific, Hemel Hempstead, UK). The gradient
was 45-100% solvent B over 18 min at a flow rate of
400 μl/min. The LC effluent was directed into the source
of a Thermo TSQ Quantum Ultra triple quadrupole mass








































































Figure 1 Low-dose aspirin decreases levels of TxB2 and
12-HETE. Concentrations of (A) TxB2 and (B) 12-HETE were reduced
in collagen-activated platelets following 75 mg aspirin oral administration
to healthy volunteers (n= 19). (C) 12-HETE:TxB2 molar ratio is elevated
following aspirin-treatment. Data are expressed as mean ± SEM.
****P< 0.0001 and ***P< 0.0005.
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tion monitoring (SRM) mode. Eicosanoids were identified
on the basis of their characteristic ion pairs (TxB2, 369/
169; PGE2-d4, 355/193; PGE2, 351/189; 12-HETE, 319/
179; 15-HETE-d8, 327/226) and matching retention time
with authentic standards. Data were acquired and analysed
using Thermo LCquan v2.6 software. Concentrations of
TxB2 and 12-HETE were determined by comparison to a
calibration curve run in parallel for each compound and
adjusted for recovery by reference to amounts of the
PGE2-d4 and 15-HETE-d8 internal standards respectively.
Statistical analysis
Data were compared with two-tailed, paired Student’s
t-test or analysed using regression analysis (Pearson’s).
A P-value of <0.05 was considered statistically signifi-
cant in all cases with data expressed as mean ± SEM.
The statistical analysis was performed using GraphPad
Prism v5.0 software.
Results
Effect of aspirin on platelet eicosanoid levels
One of the main eicosanoids detected from collagen-
stimulated platelets was TxB2, the stable isomer of TxA2
and a surrogate measure of TxA2 generation. Prior to
aspirin treatment there was a wide distribution of TxB2
concentrations in the study cohort with a mean value of
13.8 ± 1.6 ng/75 × 106 platelets (mean ± SEM). In keep-
ing with the recognised concept of aspirin activity as a
COX-1 inhibitor, oral administration of low-dose aspirin
led to a statistically significant decrease in platelet TxB2
concentrations in all of the subjects, resulting in a mean
TxB2 concentration of 1.7 ± 0.3 ng/75 × 10
6 platelets
(Figure 1A).
Interestingly, aspirin also induced a highly statistically
significant (P < 0.0001) decrease in platelet 12-HETE
generation, reducing levels prior to stimulation from a
mean of 6.2 ng to 2.9 ± 0.7 ng/75 × 106 platelets
(Figure 1B). This suggests that, in addition to inhibition
of COX-1, aspirin also impacts upon the 12-LOX path-
way to decrease 12-HETE levels. In contrast to TxB2,
12-HETE inhibition was less pronounced and more
variable among subjects (mean inhibition =53 ± 20%;
range, 20-84%), whereas TxB2 inhibition was strong and
consistent between subjects (mean inhibition =88 ± 7%;
range, 78-95%). Whilst considerable inter-subject vari-
ation in both TxB2 and 12-HETE levels pre-aspirin
treatment was observed, when the relative amounts of
TxB2 and 12-HETE were compared, the 12-HETE:TxB2
molar ratio was found to be similar in all subjects, regardless
of the initial eicosanoid concentration (Figure 1C). However,
post-aspirin treatment, this ratio was considerably higher, a
result that indicates an excess of 12-HETE compared to
TxB2 in the platelets. Concentrations of PGE2 were lowerthan TxB2 and 12-HETE, with a mean value of 0.46 ±
0.06 ng/75 × 106 platelets. Following aspirin administration
PGE2 was undetectable in the majority of samples (data not
shown).
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Figure 3 Correlations of TxB2 and 12-HETE and levels with
platelet aggregation. Post-aspirin concentrations of (A) TxB2 and (B)
12-HETE correlate with aspirin-induced reduction in platelet aggregation.
On exclusion of the point with markedly lower inhibition, the correlation
between 12-HETE levels and the platelet aggregatory response remains
statistically significant (P< 0.02).
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Considering the functional response of platelets to as-
pirin treatment, low-dose aspirin treatment significantly
(P < 0.0001) decreased the platelet aggregatory response
to collagen in all subjects (Figure 2). The greatest
observed aspirin-mediated reduction in platelet aggre-
gation was 97%, whilst the lowest reduction in aggrega-
tion caused by aspirin resulted in only a 47% decrease in
the aggregatory response.
Correlations between eicosanoid levels and platelet
aggregation
When eicosanoid levels generated from platelets post-
aspirin treatment were compared with the aspirin-induced
reduction in aggregation, a statistically significant correl-
ation (P = 0.02; Pearson correlation coefficient of r = 0.52)
was observed between TxB2 levels and aspirin-mediated
decrease in platelet aggregation (Figure 3A). Elevated
TxB2 levels were associated with smaller reductions in ag-
gregation, whilst the lowest levels of TxB2 correlated with
the greatest percentage decrease in aggregation. However,
as shown in Figure 3B, an even stronger relationship was
found to exist between post-aspirin 12-HETE levels and
the platelet aggregatory response, which was statistically
significant (P = 0.0003) and produced a Pearson correl-
ation coefficient of r =0.74. Similar to TxB2, the lowest
levels of 12-HETE correlated with the greatest aspirin-
induced reduction in aggregation.
12-LOX inhibition and platelet aggregation
To investigate a functional role for 12-HETE in platelet
aggregation, 12-LOX was inhibited using baicalein. As
shown in Figure 4A, treatment with 100 μM baicalein
significantly reduced (P = 0.032) platelet aggregation in


















Figure 2 Platelet aggregation is decreased by low-dose aspirin.
Collagen-induced platelet aggregation is significantly decreased following
oral administration of 75 mg aspirin to healthy volunteers (n= 19). Data
are expressed as mean± SEM. ****P< 0.0001.aggregation =55 ± 11%). Figure 4B shows representative
aggregometry traces. To confirm effective baicalein-
induced inhibition of 12-LOX, levels of 12-HETE were
measured by LC-MS/MS and revealed a mean reduction
in 12-HETE to 52 ± 6% with baicalein treatment.
Discussion
These findings demonstrate that, as well as inhibiting
TxA2 generation through COX-1, aspirin additionally
impacts upon 12-LOX-mediated synthesis of 12-HETE.
Whilst the effect of aspirin on TxA2 was universal
and comprehensive, indicating effective aspirin-mediated
COX-1 inhibition, the variation in efficacy on 12-HETE
inhibition was also closely associated with the extent of
inhibition of aggregation. Indeed, the subject with the
highest levels of 12-HETE was found to have the lowest
aspirin-induced reduction in platelet aggregation. This
suggests that aspirin-mediated inhibition of 12-HETE
generation may be of use in predicting the efficacy of as-
pirin with regard to platelet function. Whilst generally






































Figure 4 Inhibition of 12-LOX reduces platelet aggregation.
Platelets were pre-treated with or without 100 μM baicalein prior to
aggregation with 1.25 μg/ml collagen. Platelet aggregation was
measured for 6 min and data expressed as (A) area under the curve
(AUC). (n = 3, mean ± SEM). Panel B shows a representative
aggregometry trace.
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LOX pathway, and can reversibly inhibit 12-HETE gen-
eration in a dose-dependent manner [17,18]. This effect
appears to be unique to aspirin rather than being due to
secondary effects caused by COX inhibition as treatment
with indomethacin (COX-1 inhibitor) has no impact
upon 12-HETE levels [19].
Considerable heterogeneity of platelet response to as-
pirin was observed between the healthy volunteers in
this study, despite effective TxB2 inhibition. This obser-
vation parallels a recent study which showed that aspirin
reduced TxB2 levels in all subjects tested [20] further
supporting the notion that an alternative mechanism to
TxB2 may be involved in variable sensitivity to aspirin.
Our study examined the acute (1.5 hours) effect of as-
pirin treatment on eicosanoid levels and platelet func-
tion. Despite aspirin being an irreversible inhibitor of
platelet COX-1, it is recognised that cumulative dosing
of aspirin may be required to achieve maximal inhibition
of TxB2 generation, although how cumulative dosing ef-
fects 12-HETE inhibition are currently unknown [21].12-HETE has been suggested to play a role in platelet
function and is thought to contribute to both platelet
adhesion and aggregation [19,22] although its exact role is
unclear. Addition of 12-HpETE, the hydroperoxy precur-
sor of 12-HETE has been demonstrated to play a ‘priming’
role and increase aggregation of washed platelets [23,24].
However, other studies have shown that addition of
exogenous 12-HpETE inhibits both collagen and thrombin-
induced platelet aggregation [25,26] suggestive of anti-
aggregatory properties.
Pharmacological inhibition of 12-LOX diminishes ag-
gregation of washed platelets, further suggesting a role for
12-HETE in promoting platelet aggregation [11,27,28].
Other evidence for a pro-aggregatory role of 12-HETE
comes from a recent study that showed a significant de-
crease in aggregation of washed platelets in response to
collagen with a newly developed inhibitor, NCTT-956 that
is highly specific for 12-LOX [29]. These results are
consistent with our experimental findings using baicalein,
although it should be noted that this inhibitor may have
off-target effects on other eicosanoid pathways. The func-
tional importance of platelet 12-LOX is also emphasized
by the fact that 12-LOX-deficient mice display elevated
mortality in an ADP-induced model of thromboembolism
[30] and inhibition of 12-LOX inhibit coronary throm-
bosis in a canine model [31]. Furthermore, in patients re-
ceiving heparin treatment, platelet-derived 12-HETE has
been shown to be elevated, whilst TxB2 levels were un-
changed [32]. This was suggested as a possible mechanism
to explain the phenomenon of transient heparin-induced
platelet activation.
The signalling pathways involved in eicosanoid-dependent
platelet activation are complex and not yet fully understood.
Collagen is known to stimulate platelet 12-LOX activity via
the glycoprotein VI receptor, in a PECAM-1 and PKC-
dependent pathway [33]. Release of AA from membrane
phospholipids by PLA2 activation is a critical step in eicosa-
noid biosynthesis and a recent study has shown that COX-1
and 12-LOX are linked to different PLA2 subsets, suggesting
that TxA2 and 12-HETE are generated from different intra-
cellular pools of AA [34]. 12-HpETE is known to modulate
platelet COX activity, suggesting a degree of ‘cross-talk’ be-
tween the LOX/COX pathways although the exact mechan-
ism is unclear.
Some studies have reported a stimulatory effect of low
concentrations of 12-HpETE on COX-1 activity [30], whilst
others have shown that 12-HpETE inhibits COX-1 by alter-
ing calcium homeostasis via activation of soluble guanylate
cyclase [26]. The exact nature of the inhibitory mechanism
of aspirin on the 12-LOX pathway is unclear at present.
However, it has been suggested that aspirin exerts its im-
pact by inhibiting the glutathione peroxidase-mediated con-
version of 12-HpETE to 12-HETE, preventing 12-HETE
formation [35]. COX-1 has a bifunctional activity producing
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PGH2 via an endoperoxidase mechanism. PGH2 is then fur-
ther metabolised by various prostanoid-generating en-
zymes. This bears a striking similarity to the mechanism of
12-HETE generation, whereby 12-LOX catalyses the regio-
and stereo-specific incorporation of molecular oxygen to
form the hydroperoxide (12-HpETE), which is then re-
duced to the corresponding alcohol (12-HETE). Therefore,
it is possible that aspirin may be acting in a similar manner,
and preventing the reduction of 12-HpETE.
Aspirin remains, and is likely to remain for some time,
the mainstay of anti-platelet therapy in vascular patients
and so a full understanding of its mechanisms of action is
essential. Here we have shown for the first time a correl-
ation between aspirin-mediated platelet aggregation and
12-HETE generation. This finding highlights the import-
ance of the platelet 12-LOX pathway as an additional
mechanism by which aspirin can modulate the complex
network of AA metabolism, with potential effects on
thrombotic events. This study also underlines the import-
ance of monitoring interconnecting pathways when inves-
tigating the inhibitory mechanism of pharmacological
agents. In future work the investigation of the mechanism
and nature of aspirin inhibition of 12-LOX could be ex-
tended by using platelet markers of activation ex vivo e.g.
P-selectin, larger sample sets and disease cohorts such as
patients with type 2 diabetes or cardiovascular disease.
Conclusions
This study draws attention to the potential importance
of the 12-LOX pathway in platelet function, specifically
aspirin-mediated platelet inhibition. The findings suggest
that the variability of platelet function in response to as-
pirin is linked to the inhibition of 12-HETE generation,
which may be acting in concert with TxA2 inhibition. As
such, the work may have implications for our under-
standing into how aspirin impacts upon eicosanoid
generation.
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